AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10629515 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasted with 50 mu aluminum oxide by a microetcher
Number of subjects: 80
Study 10629515 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid etched with 37% phosphoric acid for 15 seconds
Number of subjects: 80
Study 10629515 — intervention group
Group type: EXPERIMENTAL
Intervention: Polished with pumice followed by acid etched with 37% phosphoric acid for 15 seconds
Number of subjects: 80
Study 10629515 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasted with 50 mu aluminum oxide by a microetcher followed by acid etched with 37% phosphoric acid for 15 seconds
Number of subjects: 80
Study 9106936 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg anti-TNF-alpha moab
Number of subjects: 18
Study 9106936 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg anti-TNF-alpha moab
Number of subjects: 18
Study 9106936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1337012 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 17
Study 1337012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3885891 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically supervised exercise program (N = 28)
Number of subjects: 53
Study 3885891 — intervention group
Group type: COMPARATOR
Intervention: Usual community care (N = 25)
Number of subjects: 53
Study 31235394 — intervention group
Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL)
Number of subjects: 174
Study 31235394 — intervention group
Group type: COMPARATOR
Intervention: No Question Prompt List (Control)
Number of subjects: 174
Study 28689056 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation
Number of subjects: 340
Study 28689056 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 340
Study 26108005 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 98
Study 26108005 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 98
Study 26108005 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 98
Study 26108005 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple resistance
Number of subjects: 98
Study 26108005 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-resistant strains
Number of subjects: 98
Study 26108005 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (MIC values)
Number of subjects: 98
Study 23953410 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm (40Gy to PTVelect)
Number of subjects: 200
Study 23953410 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (50Gy to PTVelect)
Number of subjects: 200
Study 23953410 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 200
Study 21196078 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterotopic noxious conditioning stimulation (HNCS)
Number of subjects: 0
Study 21196078 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (opioid antagonist)
Number of subjects: 0
Study 19216705 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepotastine 10 mg OD tablet
Number of subjects: 24
Study 19216705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17923938 — intervention group
Group type: EXPERIMENTAL
Intervention: Gpre+intra (preoperative and intraoperative active warming)
Number of subjects: 30
Study 17923938 — intervention group
Group type: EXPERIMENTAL
Intervention: Gintra (only warmed intraoperatively)
Number of subjects: 30
Study 17923938 — intervention group
Group type: COMPARATOR
Intervention: Gcontrol (preoperative and intraoperative passive thermal insulation)
Number of subjects: 30
Study 15010083 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral STN stimulation
Number of subjects: 17
Study 15010083 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched PD controls)
Number of subjects: 17
Study 11583747 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive therapy (revascularisation)
Number of subjects: 305
Study 11583747 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 305
Study 9634048 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TUVP)
Number of subjects: 104
Study 9634048 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 104
Study 7889892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (rich in n-3 fatty acids)
Number of subjects: 12
Study 7889892 — intervention group
Group type: COMPARATOR
Intervention: Mixed oil (rich in saturated fatty acids)
Number of subjects: 12
Study 7889892 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (rich in n-6 fatty acids)
Number of subjects: 12
Study 3284400 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl transdermal patches (F-TTS) 75 micrograms/h
Number of subjects: 40
Study 3284400 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 40
Study 3284400 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl transdermal patches (F-TTS)
Number of subjects: 40
Study 3284400 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl transdermal patches (F-TTS) and Placebo
Number of subjects: 40
Study 31343521 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT performed thrice weekly (HIIT×3/wk)
Number of subjects: 56
Study 31343521 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT performed twice weekly (HIIT×2/wk)
Number of subjects: 56
Study 31343521 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT performed once weekly (HIIT×1/wk)
Number of subjects: 56
Study 31343521 — intervention group
Group type: EXPERIMENTAL
Intervention: MICT performed thrice weekly (MICT×3/wk)
Number of subjects: 56
Study 31343521 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control (CON)
Number of subjects: 56
Study 27796041 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium-sugammadex (R-S)
Number of subjects: 0
Study 27796041 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine-cisatracurium-pyridostigmine (S-C-P)
Number of subjects: 0
Study 24682383 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma education program (three educational sessions)
Number of subjects: 74
Study 24682383 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 74
Study 22531622 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Garment (CG)
Number of subjects: 24
Study 22531622 — intervention group
Group type: COMPARATOR
Intervention: No Compression Garment (No CG)
Number of subjects: 24
Study 21322021 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine (2-16 mg/24 hr)
Number of subjects: 287
Study 21322021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 19818700 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 59
Study 19818700 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 59
Study 19818700 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute painful edematous stage treatment (surgery or conservative)
Number of subjects: 59
Study 19818700 — intervention group
Group type: COMPARATOR
Intervention: Operated group
Number of subjects: 59
Study 17268412 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-dosing with 5 x 100 mg LU
Number of subjects: 15
Study 17268412 — intervention group
Group type: COMPARATOR
Intervention: Without pre-dosing
Number of subjects: 15
Study 17268412 — intervention group
Group type: EXPERIMENTAL
Intervention: One week after pre-dosing
Number of subjects: 15
Study 17268412 — intervention group
Group type: EXPERIMENTAL
Intervention: Three weeks after pre-dosing
Number of subjects: 15
Study 15269081 — intervention group
Group type: EXPERIMENTAL
Intervention: Replaced UCP group (UCP replaced every 30 minutes)
Number of subjects: 80
Study 15269081 — intervention group
Group type: COMPARATOR
Intervention: Single UCP group (same UCP kept in the nappy until urine was passed)
Number of subjects: 80
Study 15269081 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups used a moisture sensitive audio alarm
Number of subjects: 80
Study 12745177 — intervention group
Group type: EXPERIMENTAL
Intervention: Salaried GP practices
Number of subjects: 20
Study 12745177 — intervention group
Group type: COMPARATOR
Intervention: Standard contract GP practices
Number of subjects: 20
Study 10594416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1%
Number of subjects: 54
Study 10594416 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.75% and Lignocaine 2%
Number of subjects: 54
Study 7560253 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg DHCl
Number of subjects: 9
Study 7560253 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg PHCl
Number of subjects: 9
Study 7560253 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg DHCl and 80 mg PHCl
Number of subjects: 9
Study 7560253 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 9
Study 2090337 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% topical ocular phenylephrine hydrochloride
Number of subjects: 200
Study 2090337 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% topical ocular phenylephrine hydrochloride
Number of subjects: 200
Study 40376 — intervention group
Group type: EXPERIMENTAL
Intervention: Dixyrazine (Esucos)
Number of subjects: 321
Study 40376 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 321
Study 40376 — intervention group
Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 321
Study 31711312 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic listening in real time (NLRT)
Number of subjects: 33
Study 31711312 — intervention group
Group type: COMPARATOR
Intervention: Phonetic transcription
Number of subjects: 33
Study 31318615 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate supplementation (0.1 mmol·kg‐1·day ‐1) for 7 days
Number of subjects: 17
Study 31318615 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 17
Study 28639995 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC (Truvada) adherence
Number of subjects: 498
Study 28639995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study 26787691 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried Blood Spot (DBS) sampling method for miltefosine quantification
Number of subjects: 16
Study 24182735 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 30
Study 24182735 — intervention group
Group type: COMPARATOR
Intervention: No EMG biofeedback
Number of subjects: 30
Study 22449646 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication switch
Number of subjects: 334
Study 22449646 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication switch plus CBT
Number of subjects: 334
Study 22449646 — intervention group
Group type: EXPERIMENTAL
Intervention: Anhedonia and CDRS-total score evaluated simultaneously
Number of subjects: 334
Study 19411105 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 44
Study 19411105 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 44
Study 16958130 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous dopaminergic stimulation (CDS)
Number of subjects: 0
Study 16958130 — intervention group
Group type: COMPARATOR
Intervention: Levodopa therapy
Number of subjects: 0
Study 15871756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Positive Expiratory Pressure (PEP) therapy, n = 11
Number of subjects: 20
Study 15871756 — intervention group
Group type: COMPARATOR
Intervention: Incentive Spirometry (IS), n = 9
Number of subjects: 20
Study 12477218 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (24 microg bid)
Number of subjects: 0
Study 12477218 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (400 microg b.i.d.)
Number of subjects: 0
Study 12477218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9536878 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% carteolol with benzalkonium chloride
Number of subjects: 30
Study 9536878 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% carteolol without benzalkonium chloride (preservative free)
Number of subjects: 30
Study 7634183 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG
Number of subjects: 42
Study 7634183 — intervention group
Group type: COMPARATOR
Intervention: FSH
Number of subjects: 42
Study 29094366 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio Skin Oil® applied for 8 weeks
Number of subjects: 80
Study 29094366 — intervention group
Group type: COMPARATOR
Intervention: Control untreated area
Number of subjects: 80
Study 26577258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program (11 patients)
Number of subjects: 21
Study 26577258 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (10 patients)
Number of subjects: 21
Study 26577258 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise myocardial perfusion SPECT
Number of subjects: 21
Study 26577258 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline to 1 month comparison
Number of subjects: 21
Study 25171033 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafted and covered with a membrane (test group)
Number of subjects: 52
Study 25171033 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 52
Study 23739063 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (9 weeks)
Number of subjects: 1010
Study 23739063 — intervention group
Group type: COMPARATOR
Intervention: No trastuzumab
Number of subjects: 1010
Study 23739063 — intervention group
Group type: EXPERIMENTAL
Intervention: PIK3CA mutations
Number of subjects: 1010
Study 20925517 — intervention group
Group type: EXPERIMENTAL
Intervention: MAF (0.5% ophthalmic solution with retention-enhancing agent)
Number of subjects: 130
Study 20925517 — intervention group
Group type: COMPARATOR
Intervention: Moxi (0.5% ophthalmic solution)
Number of subjects: 130
Study 19544682 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg diclofenac
Number of subjects: 14
Study 19544682 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg diclofenac plus B vitamins (thiamine, pyridoxine, cyanocobalamin)
Number of subjects: 14
Study 19544682 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 14
Study 16937760 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 300
Study 16937760 — intervention group
Group type: COMPARATOR
Intervention: Watchful Waiting (WW)
Number of subjects: 300
Study 12900685 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of heavy continuous running exercise at 79% of VO(2max)
Number of subjects: 6
Study 12900685 — intervention group
Group type: EXPERIMENTAL
Intervention: Strenuous intermittent exercise (treadmill running at 60, 75, 90, and 100% VO(2max))
Number of subjects: 6
Study 12900685 — intervention group
Group type: COMPARATOR
Intervention: Resting control trial
Number of subjects: 6
Study 11008908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg per day
Number of subjects: 69
Study 11008908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 11008908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 69
Study 8975169 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 33
Study 8975169 — intervention group
Group type: COMPARATOR
Intervention: Control (no ciprofloxacin)
Number of subjects: 33
Study 1348010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 12
Study 1348010 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (20 mg)
Number of subjects: 12
Study 1348010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3887555 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated naproxen tablets
Number of subjects: 12
Study 3887555 — intervention group
Group type: COMPARATOR
Intervention: Plain naproxen tablets
Number of subjects: 12
Study 29373274 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab with docetaxel
Number of subjects: 1253
Study 29373274 — intervention group
Group type: COMPARATOR
Intervention: Placebo with docetaxel
Number of subjects: 1253
Study 28701677 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan in addition to conventional diuresis therapy
Number of subjects: 29
Study 28701677 — intervention group
Group type: COMPARATOR
Intervention: Conventional diuresis therapy only (control group)
Number of subjects: 29
Study 25979186 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV) plus didanosine (ddI)‐EC/emtricitabine (FTC)
Number of subjects: 1571
Study 25979186 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) plus lamivudine‐zidovudine
Number of subjects: 1571
Study 25979186 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 1571
Study 24090189 — intervention group
Group type: EXPERIMENTAL
Intervention: Active implementation of a disease-management-programme for COPD
Number of subjects: 1372
Study 24090189 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention practices)
Number of subjects: 1372
Study 21958380 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive self-management guidance (IG)
Number of subjects: 162
Study 21958380 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 162
Study 18191455 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment (assertive community treatment, psycho-educational multi-family groups, social skills training)
Number of subjects: 328
Study 18191455 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 328
Study 16836709 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Can configuration
Number of subjects: 39
Study 16836709 — intervention group
Group type: COMPARATOR
Intervention: Lead Alone configuration
Number of subjects: 39
Study 16836709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both configurations
Number of subjects: 39
Study 12828753 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium gluconate 8% ointment
Number of subjects: 288
Study 12828753 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole 2% emulsion
Number of subjects: 288
Study 10900994 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological therapies
Number of subjects: 90
Study 10900994 — intervention group
Group type: COMPARATOR
Intervention: Self-selected treatment clients
Number of subjects: 90
Study 8648014 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 45
Study 8648014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 1505371 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef (400 mg twice daily)
Number of subjects: 100
Study 1505371 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (500/125 mg three times daily)
Number of subjects: 100
Study 6385278 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 24
Study 6385278 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 24
Study 29546280 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation during bed rest
Number of subjects: 10
Study 29546280 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control diet during bed rest
Number of subjects: 10
Study 27330150 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of 2 g tranexamic acid (TA) diluted in 200 ml of saline
Number of subjects: 739
Study 27330150 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml of saline (placebo group)
Number of subjects: 739
Study 27330150 — intervention group
Group type: COMPARATOR
Intervention: No topical administration (control group)
Number of subjects: 739
Study 24248037 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily SMS reminder
Number of subjects: 50
Study 24418871 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (Ex, n=6)
Number of subjects: 29
Study 24418871 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E and Exercise (S+Ex, n=7)
Number of subjects: 29
Study 24418871 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (S, n=8)
Number of subjects: 29
Study 20529769 — intervention group
Group type: EXPERIMENTAL
Intervention: Candid #1 vaccine (Argentina)
Number of subjects: 946
Study 20529769 — intervention group
Group type: COMPARATOR
Intervention: USA vaccine
Number of subjects: 946
Study 18387167 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis patients
Number of subjects: 23
Study 17036474 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut implantation at acupoint (Dazhui (GV 14), Jinsuo (GV 8), Fenglong (ST 40))
Number of subjects: 100
Study 17036474 — intervention group
Group type: COMPARATOR
Intervention: Sodium valproate (oral administration)
Number of subjects: 100
Study 15707013 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (20‐80 mg)
Number of subjects: 30
Study 15707013 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (5‐10 mg)
Number of subjects: 30
Study 15707013 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan and Enalapril
Number of subjects: 30
Study 11526531 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide-LAR (20 mg)
Number of subjects: 25
Study 11526531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9031963 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low dose estradiol released from a vaginal ring (Estring)
Number of subjects: 165
Study 9031963 — intervention group
Group type: COMPARATOR
Intervention: Estriol vaginal cream (Synapause)
Number of subjects: 165
Study 9031963 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 165
Study 8428468 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg) by iv infusion every 6 hrs for four doses
Number of subjects: 382
Study 8428468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 3593895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 17